



# Press Release

June 27, 2012

Rundbuckstrasse 6  
CH – 8212 Neuhausen am Rheinfall / Switzerland  
[www.lifewatch.com](http://www.lifewatch.com)

## **LifeWatch V: State-of-the-art smartphone with healthcare capabilities empowering patients and consumers**

**Neuhausen am Rheinfall / Switzerland – LifeWatch AG (SIX Swiss Exchange: LIFE), the leading wireless cardiac monitoring service and home sleep test provider in the U.S., presents today LifeWatch V, the world’s first-of-its-kind healthcare smartphone. The fully featured state-of-the-art smartphone allows patients as well as health- and wellbeing-conscious consumers to self-operate a wide range of highly valuable embedded medical sensors, wellness-related applications, cloud-based services and 24/7 call center support.**

As a next step of its product and geographical diversification LifeWatch presents today LifeWatch V, the world’s first fully featured smartphone which operates on an android OS. The state-of-the-art solution offers multiple sophisticated embedded medical miniature sensors, wellness-related applications, cloud-based services and 24/7 call center support. By using the barely visible sensors on the phone’s frame, patients as well as health- and wellbeing conscious consumers can track, capture, collect and analyze their health and medical measurements anywhere anytime. The features include ECG, body temperature, blood glucose, heart rate, blood oxygen saturation, body fat percentage and stress levels (heart rate variability). All collected data can be retrieved from the cloud for a follow-up anytime anywhere. Users can thus take corrective action, plan their diets and activities, securely share the information with a health provider or family member, trend and analyze the data and more. Patients are also able to program the unit to remind them of their drug type, dose and intake time.

### **LifeWatch V with add-on service offering**

LifeWatch V was designed with a flexible service-product ecosystem in mind, allowing easy integration of services. The LifeWatch V handset unit includes a service enablement platform to support the transmission of medical data to be analyzed, evaluated and communicated to health professionals and call center personnel around the clock. The device wirelessly interacts with a cloud-based environment allowing users direct access to a wide range of valuable complementary medical and wellness related services.

### **Strategic alliances with local partners**

Smartphones are positioned to overtake many computing functions that were reserved to computers alone. More importantly, the smartphone has emerged as an intimate device consumers carry

with them anywhere and anytime, making it an ideal vehicle to let users self-test their health, especially users with an interest in the medical field. Recent market developments have witnessed the emergence of health-dedicated cellular phones.

Based on a full and complete Go-to-Market analysis LifeWatch intends to launch the healthcare solution smartphone world-wide. In the initial markets LifeWatch has identified several local partners to enter into strategic partnerships.

<b>LifeWatch V: Medical specifications</b>	
<b>EKG (1-Lead)</b>	EKG dynamic range 0.15-5 mV. Frequency response 0.5-40 Hz. Sampling 12 bit, 250 samples /sec. Test time: Average of 35 sec.
<b>Heart rate</b>	HF measurement range 30 to 250 bpm QRS detection sensitivity > 98% QRS detection predictability > 98% Result time: Average of 10 sec.
<b>SpO2</b>	Method: Reflective R & IR emission Oxygen saturation range: 70 to 100% Accuracy: Standard deviation $\pm$ 1 digits Test time: Average of 20 sec.
<b>Glucose</b>	Range: 10-650 mg/dl Sample size: 0,4-0,7 $\mu$ L Accuracy: $\pm$ 10 mg/dL for glucose level < 75 mg/dL 12.5% for glucose level $\Rightarrow$ 75 mg/dL Test time: 3-5 sec.
<b>IR-Thermometer</b>	Range: 34 to 41 C°; Accuracy: $\pm$ 0,2 C°
<b>Body fat percentage</b>	Method: Bioelectrical Impedance
<b>Operating temperature</b>	10 to 40 C° (40 to 104 °F)
<b>LifeWatch V: Technical specifications</b>	
<b>Network</b>	3G 850/1900/2100; 2G 850/900/1800/1900; 3G (HSDPA, 7.2 Mbps)
<b>Operating system</b>	Android 2.3 (Gingerbread)
<b>Processor</b>	Qualcomm MSM7227Turbo
<b>Weight and dimensions (HxWxD)</b>	162g; 132(mm) x 70.8(mm) x 13.2(mm)
<b>Display</b>	LCD 4.3" 480*480 Pixels (WVGA)
<b>Battery capacity-</b>	1500 mAh
<b>Camera</b>	5MP main camera + 300KP front camera
<b>Connectivity</b>	Bluetooth Ver. 2.1 with BT/Wi-Fi-coexistence Wi-Fi IEEE 802.11b/g/n
<b>Memory</b>	1GB Flash, 512MB RAM, T-Flash, Micro SD Slot (up to 32GB)
<b>Certification</b>	CE- Mark pending
<b>Features</b>	GPS, A-GPS supported

**Don't miss it: Join us for a live presentation of LifeWatch V today:**

**Live demonstration:** June 27, 2012, 3:30 p.m., Zurich, Metropol, Fraumünsterstrasse 12

**Live Video Webcast** in the IR section on [www.lifewatch.com](http://www.lifewatch.com)

**Product website:** <http://www.lifewatchv.com/demo/>

**For further information please contact:**

Sensus Investor and Public Relations GmbH, Zürich:

Tel+41 433665511 | Fax+41 43 366 55 12 | Email [lifewatch@sensus.ch](mailto:lifewatch@sensus.ch)

**About LifeWatch AG**

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare technology and solution company, specializing in advanced telehealth systems and wireless remote patient monitoring services. LifeWatch services cater to individuals, ranging from high-risk and chronically ill patients, to consumers of health and wellness products. LifeWatch has subsidiaries in the United States, the Netherlands, Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is the parent company of LifeWatch Services Inc., a leading US-based cardiac monitoring service provider, and manufacturer of telecardiology products. LifeWatch is also introducing a new program for Home Sleep Testing of Obstructive Sleep Apnea (OSA) patients under the brand name NiteWatch. For additional information, please visit [www.lifewatch.com](http://www.lifewatch.com).

**Sign-up** for customized E-mail alerts and documentation requests is available at <http://production.investis.com/lifewatch/alert-service/>

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding future results of operations and financial position, business strategy and plans and objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. LifeWatch AG has based these forward-looking statements largely on current expectations and projections about future events and financial trends that it believes may affect the financial condition, results of operations, business strategy, short term and long term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. All forward-looking statements are based only on data available to LifeWatch AG at the time of the issue of this press release. LifeWatch AG does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE ISSUER.